ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
20.242,57
-0,05%
S&P 500
5.872,16
-2,95%
Dow Jones
42.326,87
-2,58%
Euro vs US Dollar
1,03787
0,28%
Bitcoin
100.352,00
0,29%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Regulus Therapeutics Inc (RGLS)

  7. Regulus Therapeutics Inc (RGLS) News

RGLS

Regulus Therapeutics (RGLS)

Regulus Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:RGLS
DatumZeitQuelleÜberschriftSymbolFirma
26/11/202414h00PR Newswire (US)Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment ConferencesNASDAQ:RGLSRegulus Therapeutics Inc
08/11/202420h17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:RGLSRegulus Therapeutics Inc
07/11/202422h26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RGLSRegulus Therapeutics Inc
07/11/202422h16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RGLSRegulus Therapeutics Inc
07/11/202422h05PR Newswire (US)Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
24/10/202422h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RGLSRegulus Therapeutics Inc
24/10/202420h02Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:RGLSRegulus Therapeutics Inc
11/10/202422h02Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:RGLSRegulus Therapeutics Inc
08/10/202414h00PR Newswire (US)Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
28/08/202414h00PR Newswire (US)Regulus Therapeutics Announces Participation at Two Healthcare Investment ConferencesNASDAQ:RGLSRegulus Therapeutics Inc
08/08/202422h24Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RGLSRegulus Therapeutics Inc
08/08/202422h16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RGLSRegulus Therapeutics Inc
08/08/202422h05PR Newswire (US)Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent UpdatesNASDAQ:RGLSRegulus Therapeutics Inc
06/08/202414h00PR Newswire (US)Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:RGLSRegulus Therapeutics Inc
29/07/202422h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
09/07/202414h00PR Newswire (US)Regulus Therapeutics Announces Participation at Two Healthcare Investment ConferencesNASDAQ:RGLSRegulus Therapeutics Inc
24/06/202416h00AllPennyStocks.comThis Biotech Wasted No Time Stealing The Premarket ShowNASDAQ:RGLSRegulus Therapeutics Inc
24/06/202413h00PR Newswire (US)Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:RGLSRegulus Therapeutics Inc
04/06/202414h00PR Newswire (US)Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® IndexesNASDAQ:RGLSRegulus Therapeutics Inc
21/05/202422h23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
21/05/202422h23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
21/05/202422h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
21/05/202422h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
21/05/202422h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
21/05/202422h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
20/05/202422h11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RGLSRegulus Therapeutics Inc
17/05/202423h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
17/05/202422h44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
17/05/202422h38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
17/05/202422h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGLSRegulus Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RGLS

Kürzlich von Ihnen besucht

EU
FR001400TNH7
New Aquitaine Region Rna...
LSE
73BZ
Hsbc Bk.26
BIT
F30745
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten